MAP1LC3B: A Protein Regulating Cell Signaling Pathways (G81631)

Target Name: MAP1LC3B

NCBI ID: G81631

MAP1LC3B

MAP1LC3B: A Protein Regulating Cell Signaling Pathways

MAP1LC3B (MAP1A/MAP1B light chain 3 B) is a protein that is expressed in various tissues and cells throughout the body. It is a key component of the light chain 3 (LC3) of the protein complex known as the light chain complex. This protein plays a crucial role in the regulation of cell signaling pathways, and is therefore of great interest as a potential drug target or biomarker.

MAP1LC3B is composed of two isoforms, a long version (MAP1LC3Blong) and a short version (MAP1LC3BShort). Both isoforms are made up of 150 amino acid residues and have similar molecular dimensions. The long isoform is predominantly expressed in muscle, while the short isoform is predominantly expressed in the brain.

MAP1LC3B is involved in the regulation of several different signaling pathways, including the T-cell signaling pathway, the neuronal signaling pathway, and the stress response pathway. It is a negative regulator of the T-cell signaling pathway, and has been shown to play a role in the regulation of T-cell proliferation and differentiation.

MAP1LC3B is also involved in the regulation of the neuronal signaling pathway. It has been shown to play a role in the regulation of neuronal excitability, and is therefore of great interest as a potential drug target for neurological disorders.

MAP1LC3B is also involved in the regulation of the stress response pathway. It has been shown to play a role in the regulation of stress responses, and is therefore of great interest as a potential drug target for stress-related disorders.

In conclusion, MAP1LC3B is a protein that is expressed in various tissues and cells throughout the body and is involved in the regulation of several different signaling pathways. It is of great interest as a potential drug target or biomarker due to its involvement in the regulation of cell signaling pathways and its role in the regulation of stress responses. Further research is needed to fully understand the role of MAP1LC3B in the regulation of cell signaling pathways and its potential as a drug target or biomarker.

Protein Name: Microtubule Associated Protein 1 Light Chain 3 Beta

Functions: Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes) (PubMed:20418806, PubMed:23209295, PubMed:28017329). Plays a role in mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production (PubMed:23209295, PubMed:28017329). In response to cellular stress and upon mitochondria fission, binds C-18 ceramides and anchors autophagolysosomes to outer mitochondrial membranes to eliminate damaged mitochondria (PubMed:22922758). While LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation (PubMed:20418806, PubMed:23209295, PubMed:28017329). Promotes primary ciliogenesis by removing OFD1 from centriolar satellites via the autophagic pathway (PubMed:24089205). Through its interaction with the reticulophagy receptor TEX264, participates in the remodeling of subdomains of the endoplasmic reticulum into autophagosomes upon nutrient stress, which then fuse with lysosomes for endoplasmic reticulum turnover (PubMed:31006537, PubMed:31006538). Upon nutrient stress, directly recruits cofactor JMY to the phagophore membrane surfaces and promotes JMY's actin nucleation activity and autophagosome biogenesis during autophagy (PubMed:30420355)

The "MAP1LC3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP1LC3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets